Patent Law Weblog
recent posts
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs – Part II
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
about
Month: July 2009
-
July 29, 2009 – Pharmaceutical Antitrust Initiatives and Developments in the U.S. and Abroad*** (American Conference Institute) – 1:00-2:30 PM (EST) July 30 – August 4, 2009 – 2009 Annual Meeting (American Bar Association) – Chicago, IL August 4, 2009 – Venue in Patent Litigation: New Strategies after Genetech and TS Tech USA (Strafford) –…
-
American Conference Institute (ACI) will be holding its 11th Advanced Forum on Biotech Patents on September 30 to October 1, 2009 in Boston, MA. The conference will allow attendees to: • Adopt a practical approach to incorporating follow-on biologics into your current patent strategies;• Implement best practices for avoiding § 112 and § 103 rejections…
-
Strafford will be offering a CLE seminar entitled: "Venue in Patent Litigation: New Strategies after Genentech and TS Tech USA" on August 4, 2009 from 1:00-2:30 PM (EST). The CLE will examine the latest case law developments on patent venue, discuss the evolving venue standards in patent litigation, and offer strategies for pursuing and defending…
-
By Sherri Oslick — On Wednesday Bristol-Myers Squibb and Medarex, Inc. announced that they have entered into a definitive merger agreement by which Bristol-Myers Squibb will acquire Medarex for $2.4 billion. With Medarex holding approximately $300 million in net cash and marketable securities, the purchase prices is effectively about $2.1 billion. Under the agreement,…
-
By Christopher P. Singer — The U.S. Patent and Trademark Office issued a press release on July 21, announcing the start of the e-Office Action program following a successful pilot version of the program. The e-Office Action program allows participating patent applicants to receive e-mail notifications of office communications, rather than receiving the usual…
-
By Christopher P. Singer — After much speculation and rumor regarding the practitioner maintenance fee (see "Annual Fee for Registered Practitioners May Be Delayed"), the U.S. Patent and Trademark Office posted an announcement clarifying that, "[t]he Final Rules adopted in November 2008 do not specify the date by which the annual fee, if collected,…
-
By Suresh Pillai — Judge Denies Attorneys Fees to Sandoz in Dispute with Sanofi-Aventis The U.S. District Court for the Central District of California denied Sandoz Inc.'s motion seeking attorneys' fees and costs in its patent infringement suit with Sanofi-Aventis. The patents-in-suit, U.S. Patent Nos. 5,389,618 and RE 38,743, cover Sanofi's anti-clotting drug, Lovenox®. …
-
By Kevin E. Noonan — Venezuelan President Hugo Chavez (at right) made headlines last month, and caused not a small amount of consternation, with the pronouncement that his government would act to prevent foreign (read: Western or U.S.) drug companies from enforcing patents to maintain high drug prices in his country. However, according to…
-
By Christopher P. Singer — As previously reported on Patent Docs, the U.S. Patent and Trademark Office (USPTO) had planned to institute an annual fee for all registered practitioners (73 Fed. Reg. 67750). The fee was intended to be required for practitioners to maintain active status to practice before the Office, and was thought…
-
By Donald Zuhn — Virginia Governor: Time Has Come to Move Forward Virginia Governor Timothy Kaine, once a candidate to be President Obama's running mate, sent a letter to the Virginia Congressional delegation at the end of June, stating that he was "encouraged by efforts in Congress to strengthen the approval process for biogeneric…
Patent Docs 